Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no ...
Regeneron Pharmaceuticals Inc.’s REGN stock is trading lower on Monday, probably in reaction to positive data from Kodiak ...
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the ...
Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye ...
Investor's Business Daily on MSN
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster ...
Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the ...
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855). Please see the full U.S. Prescribing Information for LYTENAVA here ...
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their ...
Kodiak Sciences Inc. stock jumps 140% on Phase 3 DAYBREAK wet AMD results. Click for this updated look at KOD and see if it ...
Shares of Kodiak Sciences surged more than 170% Monday—on pace for its largest one-day increase on record—after the company ...
Megan Hall: If you’re over 60 and experiencing vision loss, it’s likely you have age-related macular degeneration, or AMD. AMD blurs your central vision and makes it difficult to see details straight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results